ICER plots ear­ly sci­en­tif­ic ad­vice pro­gram for bio­phar­ma

The In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view (ICER) is look­ing to help the bio­phar­ma in­dus­try with ear­li­er re­views of clin­i­cal work, adding to their cur­rent in­de­pen­dent eval­u­a­tions of the clin­i­cal and eco­nom­ic val­ue of pre­scrip­tion drugs, med­ical tests and oth­er health in­no­va­tions.

“For some time, ICER has been re­ceiv­ing re­quests from life sci­ences com­pa­nies to help them re­think clin­i­cal tri­al de­sign, so that the tri­als more ad­e­quate­ly mea­sure the types of out­comes that mat­ter most to pa­tients and their fam­i­lies,” David Whitrap, ICER VP of com­mu­ni­ca­tions and out­reach, told Fo­cus.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER